The educational content for this website has been reviewed by a core group of healthcare professionals.

  • Professor Gordon Cook

    Photo of Professor Gordon Cook

    Professor Cook is a graduate of the University of Glasgow School of Medicine and received his higher professional training in haematology in the West of Scotland. On completion of his PhD, Professor Cook was appointed as a Consultant Haematologist in the West of Scotland before moving to take up the post of Director of Stem Cell Transplantation at Leeds Teaching Hospitals in 2002. In 2013 he was appointed as Professor of Haematology, University of Leeds where he led the myeloma clinical and translational research portfolio with a primary interest in tumour immunology and immunotherapy.

    Professor Cook is the Chair of the UK Myeloma Research Alliance (UKMRA) and National Cancer Research Institute (NCRI) Myeloma sub-group. He is also the chair of the UK Myeloma Forum and has represented the interests of both myeloma clinicians and patients in the National Institute for Health and Care Excellence Reviews.

    Professor Cook has developed and delivered an extensive national clinical research portfolio, and is currently Chief Investigator for NCRI Myeloma X, UKMRA Myeloma XII, UKMRA Myeloma XIV, MUKeight and MUKeleven. His collaboration with industry includes his position as the UK Chief Investigator for four industry international Phase III and Phase IIIb studies and he is the Chair of the Myeloma UK Research Advisory Group.

    Professor Cook holds the posts of Clinical Director of National Institute of Health Research Leeds In Vitro Diagnostics Co-operative and Clinical Director (Haematology) of Clinical Trials Research Unit, University of Leeds.

  • Professor Graham Jackson

    Photo of Professor Graham Jackson

    Professor Jackson’s research interests focus on the role of drug resistance in myeloma and he has served on advisory/clinical trial committees for Cancer Research and Bloodwise (formerly Leukaemia & Lymphoma Research). Professor Jackson has also been Chief Investigator for Myeloma XI as well as many other trials.

    Professor Jackson has been involved in writing several guidelines and has published over 200 peer-reviewed papers as well as numerous book chapters. He has given many lectures nationally and internationally. Professor Jackson has been President of the British Society of Blood and Marrow Transplantation, and the British Society for Haematology; currently he is the Scientific Secretary for the UK Myeloma Forum.


  • Dr Karthik Ramasamy

    Photo of Dr Karthik Ramasamy

    Dr Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust, Oxford, UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre. He is also Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Strategic Clinical Network, UK. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK. He is an executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance.

    Dr Ramasamy completed his internal medicine training at Nottingham, UK, and subsequently started his haematology training at Glasgow, UK. He completed a comprehensive registrar-training programme encompassing all subspecialties of haematology, including bone marrow transplantation, at King’s College London, London, UK. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London.

    Dr Ramasamy has been a Chief Investigator of myeloma studies in renal impairment and bone disease and Principal Investigator on several myeloma trials. Dr Ramasamy’s translational research interests are therapeutic manipulation of marrow microenvironment, myeloma bone disease and myeloma drug resistance mechanisms.

  • Professor Guy Pratt

    Photo of Professor Guy Pratt

    Professor Pratt is a Consultant Haematologist at the Queen Elizabeth (QE) Hospital, Birmingham. His main research interests are multiple myeloma, chronic lymphocytic leukaemia and Waldenstroms Macroglobulinaemia, and include T cell immunity, exploring biomarkers in these diseases and clinical trials. Professor Pratt has developed a large number of collaborations nationally and has a growing publication output (over 120 peer-reviewed publications). He was the lead for developing and promoting guidelines relating to plasma cell disorders for the UK Myeloma Forum between 2011 to 2017, including being the Clinical Lead for the 2016 National Institute for Health and Care Excellence myeloma guidelines. Professor Pratt was a trustee for the British Society of Haematology 2015-2018. He is now scientific secretary for the British Society of Haematology, secretary for the UK Myeloma Forum, and a trustee for WMUK (Waldenstrom’s Macroglobulinemia) and Cure Leukaemia.

  • Ms Sarah Henshaw

    Photo of Ms Sarah Henshaw

    Sarah Henshaw has been the Myeloma Clinical Nurse Specialist at the Nottingham Centre for Clinical Haematology for 11 years, and was a Trustee of The Basil Skyers Myeloma Foundation since its inception until June 2018.

    Ms. Henshaw developed her interest in myeloma while she was working as a Staff Nurse in haematology at a local district general hospital. She also worked as a Staff Nurse and Clinical Nurse Educator at Nottingham University Hospital before becoming a Myeloma Clinical Nurse Specialist in April 2007. Recently she has become involved with an international working group of Myeloma CNS’s where she hopes to impact on the IMW nursing programme. In addition, she is in the early phases of setting up a National Myeloma Nurse Network in conjunction with the UK Myeloma Forum. It is hoped this group will help standardise myeloma nursing care, share best practice, plug gaps in myeloma nurse related published work, develop protocols and develop nurse education.

    Ms. Henshaw has set up and run four independent nurse-led clinics primarily managing patients’ pain and symptoms from their myeloma and associated treatments and monoclonal gammopathy of undetermined significance. Her particular interests are quality of life for myeloma patients, pain management, late effects and the progression of new treatments. Following her Bachelor’s degree in Health Care Studies, specialising in haemato-oncology, she became an independent nurse prescriber and uses this skill extensively in her nurse led clinics. She is also undertaking an MSc in Health and Social Care specialising in palliative and end of life care.

  • Ms Christine Skeet

    Photo of Ms Christine Skeet

    Christine Skeet is a Myeloma Clinical Nurse Specialist at Derby Teaching Hospitals NHS Foundation Trust. She started her nurse training at the University of Birmingham in 2001, working in various hospitals throughout the West Midlands during this time.

    Graduating in 2004 with a Bachelor of Nursing (Hons) degree, her first job was in haematology. Christine initially worked at the Queen Elizabeth Hospital in Birmingham on the inpatient haematology ward, before moving on to the bone marrow transplant unit for three years. She relocated to Derby in 2008, working on the haematology day unit before becoming a Clinical Nurse Specialist in 2009.

    Ms. Skeet has since specialised in myeloma, and is very privileged to meet and support many inspiring patients and enjoys working with an excellent team of doctors and nurses on a daily basis. She is particularly interested in supporting patients to live well with myeloma, and helped to set up the Derby Myeloma Support Group.

  • Dr Sally Moore

    Photo of Dr Sally Moore

    Dr Sally Moore undertook her specialist registrar training in haematology at University College London Hospital (UCLH). Here, she worked as a Clinical Fellow in myeloma alongside Professor Kwee Yong and her research included overseeing trial patients and publishing clinical outcomes. In addition, she undertook laboratory research investigating myeloma bone disease at the UCLH Cancer Centre.

    Dr Moore relocated to Bath in 2013 upon taking up a Consultant post. Since moving to Bath, she has established a specialist myeloma clinic, a successful myeloma support group, has an ever-expanding clinical trial portfolio and is working hard to raise the profile of myeloma within the hospital and community. She is also a member of the myeloma team at the Churchill Hospital Oxford.

    In 2015, Dr Moore established the Southwest Myeloma Group, inviting colleagues from across the Southwest of England to meet, share ideas and best practice in addition to providing an educational forum.

    Dr Moore has worked as an advisor for pharmaceutical companies specialising in myeloma and is in the preliminary stages of developing a myeloma registry in collaboration with Myeloma UK. She is also collaborating with the University of Bath in investigating the impact exercise may have on disease progression in MGUS and smouldering myeloma and assessing the role of pre-habilitation and re-habilitation in transplant recipients.

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.